<DOC>
	<DOCNO>NCT00085943</DOCNO>
	<brief_summary>This study compare ability fosamprenavir 700 mg ritonavir 100 mg twice day lopinavir 400 mg ritonavir 100 mg twice day combine fix dose combination tablet abacavir 600 mg lamivudine 300 mg day suppress virus level HIV le 400 copies/mL blood . In addition study safety tolerability compound 48 week study period patient naive anti-HIV therapy .</brief_summary>
	<brief_title>KALETRA Or LEXIVA With Ritonavir Combined With EPIVIR And Abacavir In Naive Subjects Over 48 Weeks</brief_title>
	<detailed_description>A Phase IIIB , Randomized , Open-Label , Multicenter Study Safety Efficacy GW433908 ( 700mg BID ) plus ritonavir ( 100mg BID ) Versus Lopinavir/ritonavir ( 400mg/100mg BID ) Administered Combination Abacavir/Lamivudine ( 600mg/300mg ) Fixed-Dose Combination Tablet QD Antiretroviral-Naive HIV-1 Infected Adults Over 48 Weeks</detailed_description>
	<mesh_term>Infection</mesh_term>
	<mesh_term>Communicable Diseases</mesh_term>
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Immunologic Deficiency Syndromes</mesh_term>
	<mesh_term>Acquired Immunodeficiency Syndrome</mesh_term>
	<mesh_term>Ritonavir</mesh_term>
	<mesh_term>Fosamprenavir</mesh_term>
	<mesh_term>Lopinavir</mesh_term>
	<mesh_term>Abacavir</mesh_term>
	<mesh_term>Lamivudine</mesh_term>
	<mesh_term>Dideoxynucleosides</mesh_term>
	<criteria>HIV infected subject naive antiHIV therapy . History positive HIV test . At least 1000 copies/mL HIV blood screening . Active HIVrelated disease . Taking investigational drug . Pregnant breastfeeding female . Not suitable participate per investigator opinion .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2011</verification_date>
	<keyword>ritonavir</keyword>
	<keyword>abacavir</keyword>
	<keyword>HIV</keyword>
	<keyword>lopinavir</keyword>
	<keyword>lamivudine</keyword>
	<keyword>fosamprenavir</keyword>
	<keyword>Epzicom</keyword>
</DOC>